Prime Medicine Common Etf Performance
| PRME Etf | USD 3.27 0.06 1.80% |
The etf holds a Beta of 1.36, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Prime Medicine will likely underperform.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Prime Medicine Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Etf's primary indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the fund shareholders. ...more
1 | Prime Medicine Trading Down 7.3 percent Whats Next | 12/03/2025 |
2 | ETF Prime Solving Advisor Needs With Goals-Based Strategies - ETF Trends | 12/11/2025 |
3 | Brokerages Set Prime Medicine, Inc. Target Price at 7.45 | 12/24/2025 |
4 | Prime Medicine, Inc. Announces NEJM Publication Of PM359 Data | 12/31/2025 |
5 | Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference | 01/07/2026 |
6 | ETF Prime Grading 2026 ETF Predictions - ETF Trends | 01/21/2026 |
7 | ETF Prime International Stocks Lead Flows - ETF Trends | 02/20/2026 |
| Begin Period Cash Flow | 55.1 M | |
| Total Cashflows From Investing Activities | 68.5 M | |
| Free Cash Flow | -130.2 M |
Prime Medicine Relative Risk vs. Return Landscape
If you would invest 379.00 in Prime Medicine Common on November 22, 2025 and sell it today you would lose (49.00) from holding Prime Medicine Common or give up 12.93% of portfolio value over 90 days. Prime Medicine Common is currently does not generate positive expected returns and assumes 5.0809% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of etfs are less volatile than Prime, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Prime Medicine Target Price Odds to finish over Current Price
The tendency of Prime Etf price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.27 | 90 days | 3.27 | more than 94.0 |
Based on a normal probability distribution, the odds of Prime Medicine to move above the current price in 90 days from now is more than 94.0 (This Prime Medicine Common probability density function shows the probability of Prime Etf to fall within a particular range of prices over 90 days) .
Prime Medicine Price Density |
| Price |
Predictive Modules for Prime Medicine
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Prime Medicine Common. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Prime Medicine Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Prime Medicine is not an exception. The market had few large corrections towards the Prime Medicine's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Prime Medicine Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Prime Medicine within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.02 | |
β | Beta against Dow Jones | 1.36 | |
σ | Overall volatility | 0.33 | |
Ir | Information ratio | 0 |
Prime Medicine Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Prime Medicine for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Prime Medicine Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Prime Medicine generated a negative expected return over the last 90 days | |
| Prime Medicine has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.98 M. Net Loss for the year was (195.88 M) with loss before overhead, payroll, taxes, and interest of (154.05 M). | |
| Prime Medicine Common currently holds about 146.66 M in cash with (122.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: ETF Prime International Stocks Lead Flows - ETF Trends | |
| The fund maintains 99.55% of its assets in stocks |
Prime Medicine Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Prime Etf often depends not only on the future outlook of the current and potential Prime Medicine's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Prime Medicine's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 118.6 M | |
| Cash And Short Term Investments | 190.4 M |
Prime Medicine Fundamentals Growth
Prime Etf prices reflect investors' perceptions of the future prospects and financial health of Prime Medicine, and Prime Medicine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prime Etf performance.
| Return On Equity | -1.12 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (44.06) % | ||||
| Current Valuation | 498.73 M | ||||
| Shares Outstanding | 180.51 M | ||||
| Price To Earning | 14.40 X | ||||
| Price To Book | 3.67 X | ||||
| Price To Sales | 100.57 X | ||||
| Revenue | 2.98 M | ||||
| EBITDA | (196.34 M) | ||||
| Cash And Equivalents | 146.66 M | ||||
| Cash Per Share | 6.39 X | ||||
| Total Debt | 40.79 M | ||||
| Debt To Equity | 0.18 % | ||||
| Book Value Per Share | 0.92 X | ||||
| Cash Flow From Operations | (122.86 M) | ||||
| Earnings Per Share | (1.42) X | ||||
| Total Asset | 297.51 M | ||||
| Retained Earnings | (687.21 M) | ||||
About Prime Medicine Performance
By analyzing Prime Medicine's fundamental ratios, stakeholders can gain valuable insights into Prime Medicine's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Prime Medicine has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Prime Medicine has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.| Prime Medicine generated a negative expected return over the last 90 days | |
| Prime Medicine has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.98 M. Net Loss for the year was (195.88 M) with loss before overhead, payroll, taxes, and interest of (154.05 M). | |
| Prime Medicine Common currently holds about 146.66 M in cash with (122.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: ETF Prime International Stocks Lead Flows - ETF Trends | |
| The fund maintains 99.55% of its assets in stocks |
Other Information on Investing in Prime Etf
Prime Medicine financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine security.